- ‘We follow stringent standards to ensure safety and quality’ says GM
- Low-dose aspirin tablet recalled due to stability issues
Ras Al Khaimah (UAE): Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, has issued a statement reinforcing its commitment to quality following the recall of one of its products by the UAE Ministry of Health and Prevention (MoHAP).
Jerome Carle, General Manager of Julphar, said: We can confirm that low-dose aspirin medicine, Jusprin 81mg, has been recalled by MoHAP due to an issue over its stability.
“The global nature of our business requires that the Julphar system has the highest standards and processes to ensure consistent quality across our entire value chain – from the supply of materials through to manufacturing and approval by the leading authorities in the world.
“Our consumers deserve safe, effective and quality products, and across the Julphar system, we work hard to meet the highest standards of safety and quality. We follow stringent procedures designed to ensure the safety and quality of each of our products.
Our scientific teams are working hand in hand with MOHAP and we are following their recommendations to the letter to ensure a quick resolution.”
Julphar is one of the largest pharmaceutical manufacturers in the Middle East and Africa and for almost four decades, the company has been delivering high quality, innovative and affordable healthcare solutions to families across the globe. Established under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi in 1980, Julphar employs more than 5,000 people and distributes pharmaceutical products to 50 countries on five continents.
Julphar’s business is centered on three core business units – Julphar Diabetes Solutions, General Medicines and its consumer division, Julphar Life – which target major therapeutic segments including Gastrology, Pain Management, Wound Care, Antibiotics and Cardio-metabolism. Julphar has 16 internationally accredited facilities in Africa, Middle East and Asia that produce more than a million boxes of medicine a day. In 2012, Julphar became one of the largest producers of insulin in the world.
For more information, visit www.julphar.net
For media enquiries, please contact:
T: +971 7 246 1461
M: +971 58 263 3997
© Press Release 2019